MRK vs NVDA
MRK: Merck & Co. is a leading global biopharmaceutical firm dedicated to delivering life-saving vaccines and innovative therapeutic medicines for major disease areas. NVDA: The world's leading AI infrastructure company, providing accelerated computing GPUs and software platforms that power large-scale data center AI, deep learning, and scientific computing workloads.
Side-by-side fundamentals
| Metric | MRK | NVDA | Edge |
|---|---|---|---|
| Price as of 2026-08-13 close | $135.55 | $225.30 | |
| Market cap as of 2026-08-14 | $334.4B | $5.45T | |
| P/E as of 2026-08-14 | 103.86 | 33.98 | NVDA lower |
| PEG as of 2026-08-14 | 4.91 | 0.58 | NVDA lower |
| Net margin as of 2026-08-14 | +4.8% | +63.0% | NVDA higher |
| Gross margin as of 2026-08-14 | +77.3% | +74.2% | MRK higher |
| Operating margin as of 2026-08-14 | +9.6% | +64.0% | NVDA higher |
| ROE as of 2026-08-14 | +17.9% | +111.7% | NVDA higher |
| ROA as of 2026-08-14 | +7.0% | +83.1% | NVDA higher |
| Debt / equity as of 2026-08-14 | 1.07 | 0.04 | NVDA lower |
| Revenue growth (YoY) as of 2026-08-14 | +4.6% | +70.7% | NVDA higher |
| Revenue CAGR (3y) SEC XBRL | +3.1% | +100.0% | NVDA higher |
| Dividend yield as of 2026-08-14 | +2.5% | +0.4% | MRK higher |
| Dividend streak (yrs) SEC XBRL | 5 | 4 | MRK higher |
| Beta as of 2026-08-14 | 0.21 | 2.25 | |
| 1-year return as of 2026-08-13 close | +63.9% | +24.1% | MRK higher |
Fundamentals: market data, as of 2026-08-14. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-13.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.